Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Diabetes
•
Gastroenterology
•
Neurology
•
Autonomic Neurology
•
Endocrinology
•
Neuro-Gastroenterology
•
Gastrointestinal Functional & Motility Disorders
Do 5HT4 agonists such as Metoclopramide actually lead to improvement in symptoms for patients with diabetes related gastroparesis?
Related Questions
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
How do you counsel patients on the use of compounded weight loss medications?
Do you recommend neuromodulation treatments with an implantable device for patients with chronic painful diabetic neuropathy who have not responded to common oral therapies such as Gabapentin and Amitriptyline?
Should GLP1 R agonists be used as first line glucose lowering agents in patients with ESKD and DM2?
Is there a particular prokinetic agent that you recommend if a patient has failed both PPI and TCA in the treatment of suspected functional dyspepsia?
How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?
How would you approach additional workup and management of a patient with active Crohn’s disease, who has multiple lung and brain nodules, with lung pathology demonstrating necrotizing granulomatous inflammation and brain biopsy with granulomatous inflammation and medium-large vessel vasculitis?
What is the typical timeline for remission of autoimmune hypoglycemia?
Should we be using body fat percentage instead of BMI for determining patients' risk of metabolic syndrome?
Do you recommend early oral nutrition when managing diabetic ketoacidosis?
